Weight loss GLP-1 drugs craze drives new packages with diagnostics, lifestyle coaching, and drug delivery

GLP-1

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Diagnostic majors, online pharmacies, hospitals and wellness platforms are rolling out packages to capture a slice of the fast‑growing weight-loss market that blends GLP-1 medications with doctor‑led programs, diagnostics bundles, medication logistics, and lifestyle coaching.

The executives of the companies say by pairing weight-loss drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) with diet plans, lab monitoring, and strength training, patients will achieve safer, sustained results.

India’s GLP‑1 category has scaled nearly 10× in five years to Rs 1,047 crore for year ended November 2025. Demand is urban‑skewed, with Mumbai MMR up 297% and West/North zones leading growth as affordability and awareness improve. In November alone, the market doubled year‑on‑year, with Mounjaro holding the lead and Wegovy catching up after mid‑November price cuts.

Metropolis Healthcare and Thyrocare, two large diagnostic chains, have launched GLP‑1 monitoring panels nationwide in recent weeks to establish pre‑therapy baselines and track treatment safety—covering glucose–insulin balance, cardiac risk, liver–kidney function, nutrition markers (B12, D), and red‑flag parameters like amylase/lipase for pancreatitis risk and thyroid function for rare adverse effects.

"As GLP‑1 therapies gain traction across India, they must be supported by a reliable diagnostic framework. Many individuals start or continue treatment without clear insight into metabolic status or how their body is responding,” said Surendran Chemmenkotil, MD, Metropolis Healthcare. “These specialised GLP‑1 packages enhance clinical decision‑making and make metabolic monitoring accessible and meaningful,” he added.

Rahul Guha, MD & CEO, PharmEasy and Thyrocare Technologies, said, “These therapies are powerful and effective when used responsibly, but they work best with consistent monitoring. Our GLP‑1 packages are designed to make that process easier and more affordable nationwide."

On the care‑delivery side, wellness platform Healthify (formerly HealthifyMe) launched HealthifyRx —a doctor‑supervised GLP‑1 program that integrates lab testing, dose titration, nutrition coaching, strength plans and taper protocols, with Tata 1mg powering medicines and diagnostics.

The platform says its five‑phase protocol, spanning activation, momentum, acceleration, plateau defence, and off‑ramp, is designed to preserve muscle mass and reduce rebound once medication is tapered.

Not to left behind are hospital chains. Narayana Health, Max Healthcare, Apollo Hospitals among others, are offering medically supervised GLP‑1 therapy programs for weight loss. These programs include doctor consultations to assess eligibility, prescription of GLP‑1 drugs such as Ozempic (semaglutide) or Mounjaro (tirzepatide), and integration with lifestyle interventions like diet planning and exercise coaching.

Ambrish Mithal, Chairman of Endocrinology, Max Healthcare told Moneycontrol GLP-1 medication alone cannot deliver lasting results.

“Combining medical therapy with structured lifestyle interventions—covering nutrition, strength training, and behavioral change—lays the groundwork for lasting metabolic health,” Mittal said.

Online pharmacies like Tata 1mg and PharmEasy are also leaning in. The sector’s leaders are merchandising GLP‑1 pens and bundling lab checks with tele‑consults to improve adherence and safety. Executives point to pen‑format convenience and nationwide delivery as catalysts for uptake—paired with programs that require doctor consultation to determine suitability and dose.